December 10, 2015

Even More of What's Hot in Immuno-Oncology Licensing

This live web panel, which took place on December 10, 2015, is the continuation of the discussion started on October 6. Hosted by ShareVault, Defined Health, Pullan Consulting, the Licensing Executives Society, the Trout Group and the Biotechnology Industry Organization (BIO), the panelists continued to discuss what's exciting and not so exciting in immuno-oncology drug development, and why.

Biotech licensing and pharmaceutical business development consultant Linda Pullan was joined by four panelists who are business development experts from global pharmaceutical companies, a leading academic cancer center, and a top business development consulting firm. 

The panelists started off by summarizing their previous discussion and recapping the main points. The topics covered in the continued discussion include:

  • Cell Recruitment
  • Innate Immunity
  • Other Approaches
  • Licensing Criteria
  • Biomarkers
  • Strategy
  • Deal terms
  • And more...

If you are developing an immuno-oncology drug or working toward in- or out-licensing one, you will want to hear these perspectives.

request the recording of
the web panel discussion




ShareVault’s secure document sharing solution gives pharmaceutical and biotechnology  organizations the confidence to simply and securely share sensitive documents with third parties during due diligence, product development, technology transfers, fundraising, partnering, collaborative research and other activities that require the highest level of document security.

Compared to consumer-grade solutions, ShareVault virtual data rooms offer many features that give you control and document intelligence with the highest level of document-protection and monitoring available. Learn more.